A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.

Paolo Ragonese, Nunzia Alessandra Losignore, Antonella Veneziano, Antonello Pala, Ada Francia, Antonello Pala, Katrin Plewnia, Mariarosa Rottoli, Davide Maimone, Maura Frigo, Paolo Confalonieri, Enrico Montanari

Risultato della ricerca: Articlepeer review

3 Citazioni (Scopus)

Abstract

INTRODUCTION: Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis.METHODS: POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale - Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12months (via HADS).RESULTS: Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36.CONCLUSION: In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect in patients with measurable anxiety or depression at baseline.
Lingua originaleEnglish
pagine (da-a)105-109
Numero di pagine5
RivistaJournal of the Neurological Sciences
Volume364
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2800.2808???
  • ???subjectarea.asjc.2700.2728???

Fingerprint

Entra nei temi di ricerca di 'A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.'. Insieme formano una fingerprint unica.

Cita questo